NF-κB mediates aberrant activation of HIF-1 in malignant lymphoma

Experimental Hematology

Volumn 38, Issue 12, 2010, Pages 1199-1208

  Qiao, Qiao ^a,b   Nozaki, Yumi ^a   Sakoe, Kumi ^a   Komatsu, Norio ^a,c   Kirito, Keita ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; SHORT HAIRPIN RNA; SURVIVIN;

ARTICLE; B LYMPHOCYTE; BINDING SITE; CANCER RADIOTHERAPY; CELL DEATH; CELL PROTECTION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IONIZING RADIATION; LYMPHOMA; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN TARGETING; RADIATION EXPOSURE; RADIOSENSITIVITY; REPORTER GENE; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL LINE, TUMOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHOMA; MICROTUBULE-ASSOCIATED PROTEINS; NF-KAPPA B; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 78549245097     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.08.007     Document Type: Article

References (34)

1. Semenza G.L. Life with oxygen. Science (New York, NY) 2007, 318:62-64.
2. Semenza G. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29:625-634.
3. Hu Y., Kirito K., Yoshida K., et al. Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. Mol Cancer Ther 2009, 8:2329-2338.
4. Ghosh A.K., Shanafelt T.D., Cimmino A., et al. Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood 2009, 113:5568-5574.
5. Evens A.M., Schumacker P.T., Helenowski I.B., et al. Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family. Br J Haematol 2008, 141:676-680.
6. Giatromanolaki A., Koukourakis M.I., Pezzella F., et al. Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin's lymphomas and correlate with hypoxia inducible factor activation. Hematol Oncol 2008, 26:219-224.
7. Passam F.H., Alexandrakis M.G., Kafousi M., et al. Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma. Pathol Res Pract 2009, 205:11-20.
8. Lenz G., Davis R.E., Ngo V.N., et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (New York, NY) 2008, 319:1676-1679.
9. Jost P.J., Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007, 109:2700-2707.
10. van Uden P., Kenneth N.S., Rocha S. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J 2008, 412:477-484.
11. Belaiba R.S., Bonello S., Zahringer C., et al. Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol Biol Cell 2007, 18:4691-4697.
12. Rius J., Guma M., Schachtrup C., et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008, 453:807-811.
13. Kirito K., Fox N., Kaushansky K. Thrombopoietin induces HOXA9 nuclear transport in immature hematopoietic cells: potential mechanism by which the hormone favorably affects hematopoietic stem cells. Mol Cell Biol 2004, 24:6751-6762.
14. Sakoe Y., Sakoe K., Kirito K., Ozawa K., Komatsu N. FOXO3A as a key molecule for all-trans retinoic acid-induced granulocytic differentiation and apoptosis in acute promyelocytic leukemia. Blood 2010, 115:3787-3795.
15. Mizukami Y., Li J., Zhang X., Zimmer M.A., Iliopoulos O., Chung D.C. Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res 2004, 64:1765-1772.
16. Choi S., Kim J.H., Roh E.J., Ko M.J., Jung J.E., Kim H.J. Nuclear factor-kappaB activated by capacitative Ca2+ entry enhances muscarinic receptor-mediated soluble amyloid precursor protein (sAPPalpha) release in SH-SY5Y cells. J Biol Chem 2006, 281:12722-12728.
17. Tobe M., Isobe Y., Tomizawa H., Nagasaki T., Takahashi H., Hayashi H. A novel structural class of potent inhibitors of NF-kappa B activation: structure-activity relationships and biological effects of 6-aminoquinazoline derivatives. Bioorg Med Chem 2003, 11:3869-3878.
18. Juliger S., Goenaga-Infante H., Lister T.A., Fitzgibbon J., Joel S.P. Chemosensitization of B-cell lymphomas by methylseleninic acid involves nuclear factor-kappaB inhibition and the rapid generation of other selenium species. Cancer Res 2007, 67:10984-10992.
19. Habraken Y., Piette J. NF-kappaB activation by double-strand breaks. Biochem Pharmacol 2006, 72:1132-1141.
20. Rezvani H.R., Dedieu S., North S., et al. Hypoxia-inducible factor-1α, a key factor in the keratinocyte response to UVB exposure. J Biol Chem 2007, 282:16413-16422.
21. Kim W.Y., Oh S.H., Woo J.K., Hong W.K., Lee H.Y. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Res 2009, 69:1624-1632.
22. Weston V.J., Austen B., Wei W., et al. Apoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukemia frequently involves increased NF-kappaB survival pathway signaling. Blood 2004, 104:1465-1473.
23. Evens A.M., Sehn L.H., Farinha P., et al. Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2010, 28:1017-1024.
24. Jazirehi A.R., Huerta-Yepez S., Cheng G., Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005, 65:264-276.
25. Guzy R.D., Sharma B., Bell E., Chandel N.S., Schumacker P.T. Loss of the SdhB, but not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis. Mol Cell Biol 2008, 28:718-731.
26. Selak M.A., Armour S.M., MacKenzie E.D., et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005, 7:77-85.
27. Moeller B.J., Cao Y., Li C.Y., Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004, 5:429-441.
28. Ahmed K.M., Li J.J. NF-kappa B-mediated adaptive resistance to ionizing radiation. Free Radic Biol Med 2008, 44:1-13.
29. Kirito K., Fox N., Komatsu N., Kaushansky K. Thrombopoietin enhances expression of vascular endothelial growth factor (VEGF) in primitive hematopoietic cells through induction of HIF-1alpha. Blood 2005, 105:4258-4263.
30. Kojima H., Kobayashi A., Sakurai D., et al. Differentiation stage-specific requirement in hypoxia-inducible factor-1{alpha}-regulated glycolytic pathway during murine B cell development in bone marrow. J Immunol 2010, 184:154-163.
31. Adida C., Haioun C., Gaulard P., et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000, 96:1921-1925.
32. Schlette E.J., Medeiros L.J., Goy A., Lai R., Rassidakis G.Z. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 2004, 22:1682-1688.
33. Tolcher A.W., Mita A., Lewis L.D., et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008, 26:5198-5203.
34. Chen N., Chen X., Huang R., et al. BCL-xL Is a target gene regulated by hypoxia-inducible factor-1α. J Biol Chem 2009, 284:10004-10012.